Oxygen Of The Saccharide Radical Bonded Directly To A Polycyclo Ring System Of Three Or More Carbocyclic Rings Patents (Class 514/33)
  • Publication number: 20120058965
    Abstract: Provided herein are bitter taste receptor ligands, related agents, combinations, compositions, methods and systems for modulating release of a metabolic hormone in vitro or in vivo from cells of the GI tract of an individual.
    Type: Application
    Filed: June 17, 2011
    Publication date: March 8, 2012
    Inventors: William A. GODDARD, III, Mark MENNA, Stephen PANDOL, Ravinder ABROL
  • Publication number: 20120053142
    Abstract: The invention relates to compositions comprising at least one xanthine compound, preferably further comprising at least one agent which acts on capillary circulation and/or at least one natural moisturizing agent, which can be used to treat, or to reduce and/or minimize the appearance of, defects such as dark circles, bags and/or puffiness around eyes.
    Type: Application
    Filed: November 3, 2011
    Publication date: March 1, 2012
    Applicant: L'Oreal S.A.
    Inventor: Isabelle TERRISSE
  • Publication number: 20120053141
    Abstract: The present invention pertains to novel uses of glycyrrhetinic acid (GA), glycyrrhizic acid (GLA) and related compounds for prevention and/or treatment of pulmonary fibrosis, in particular, irradiation-induced pulmonary fibrosis. Also embodied are therapeutic uses of prodrugs, metabolites, derivatives (e.g., acids, esters and ethers), and salts of glycyrrhetinic acid (GA) and glycyrrhizic acid (GLA). The present invention also provides for therapeutic or pharmaceutical compositions comprising a compound of the invention in a form that can be combined with a pharmaceutically acceptable carrier.
    Type: Application
    Filed: August 25, 2010
    Publication date: March 1, 2012
    Inventors: Lurong ZHANG, Weijian Zhang, Jianhua Xu, Shanmin Yang
  • Publication number: 20120052121
    Abstract: Pharmaceutical composition containing a combination of a non steroidal anti inflammatory drug and a colchicoside derivative, the active ingredients being present in the free state or in the form of a salt.
    Type: Application
    Filed: July 22, 2011
    Publication date: March 1, 2012
    Applicant: SANOFI
    Inventors: Praveen KHULLAR, Mansing SHINGTE, Shirishbhai PATEL, Suseendharnath A, Krishna RAJU, Vanga REDDY
  • Publication number: 20120042894
    Abstract: The invention relates to a composition for caring for human keratinous fibres comprising, in a physiologically acceptable medium: a) at least one compound chosen from arginines, their organic or inorganic acid salts and their derivatives; b) at least one compound of the formula (I) in which R1=H or —CH3; R2=H or —CH3; R3=—CH3, R1 and R2 not simultaneously being H, or else a Centella asiatica extract comprising a compound or a mixture of compounds of formula (I); and optionally c) at least one compound of formula (II) in which w+x+y+z has a mean value of 4.
    Type: Application
    Filed: March 10, 2010
    Publication date: February 23, 2012
    Applicant: L'OREAL
    Inventors: Isabelle Jacquier, Jean-Francois Nadaud
  • Publication number: 20120028916
    Abstract: The present invention related to cosmetic compositions comprising oridonin and new cosmetic uses. Oridonin is used for fighting the signs of cutaneous aging and for slimming. A composition comprising a combination of oridonin and darutigenol or a derivative thereof, in particular darutoside, is disclosed together with the cosmetic use of such composition.
    Type: Application
    Filed: April 15, 2010
    Publication date: February 2, 2012
    Applicant: SEDERMA
    Inventors: Arnaud Fournial, Philippe Mondon
  • Publication number: 20110293691
    Abstract: Provided herein are multimodal barrier materials useful for preventing adhesions in a subject, which may include a collagen, a collagen deposition inhibitor and/or a chitosan.
    Type: Application
    Filed: April 28, 2011
    Publication date: December 1, 2011
    Inventors: Kurt R. Weber, Steve J. Hodges, Scott A. Washburn
  • Publication number: 20110294752
    Abstract: The invention provides novel saponin mixtures and compounds which are isolated from the species Acacia victoriae and methods for their use. These compounds may contain a triterpene moiety, such as acacic or oleanolic acid, to which oligosaccharides and monoterpenoid moieties are attached. The mixtures and compounds have properties related to the regulation of apoptosis and cytotoxicity of cells and exhibit potent anti-tumor effects against a variety of tumor cells.
    Type: Application
    Filed: June 14, 2011
    Publication date: December 1, 2011
    Applicant: RESEARCH DEVELOPMENT FOUNDATION
    Inventors: Charles J. Arntzen, Mary E. Blake, Jordan U. Gutterman, Joseph J. Hoffmann, Gamini S. Jayatilake, David T. Bailey
  • Publication number: 20110275584
    Abstract: The present invention relates to the use of an 11-?-HSD-type 1 and/or type 2 inhibitor for the manufacture of a pharmaceutical agent for the prevention and/or treatment of inflammation-induced and/or immune-mediated loss of bone and/or cartilage.
    Type: Application
    Filed: May 11, 2011
    Publication date: November 10, 2011
    Applicant: Onepharm Research and Development GmbH
    Inventors: Thomas WILCKENS, Ariane VOLKMANN
  • Publication number: 20110274656
    Abstract: The present invention relates to a pharmaceutical composition for preventing or treating Hepatitis C, comprising the roots extract of Platycodon grandiflorum and/or saponin components in Platycodon grandiflorum useful as an antiviral agent. The composition of the present invention has no harm to human and inhibits the proliferation of Hepatitis C virus, so that it can be effectively used as a preventive or therapeutic agent for Hepatitis C.
    Type: Application
    Filed: January 21, 2010
    Publication date: November 10, 2011
    Applicant: B&C Biopharm Co., Ltd.
    Inventors: Jong Woo Kim, Sang Wook Lee, Sang Jin Park, Jung Cheul Shin, Jae Won Yang, Jong Hwan Lim
  • Publication number: 20110263521
    Abstract: The invention relates to a pharmaceutical or cosmetic composition for topical and/or parenteral application comprising, in a physiologically acceptable medium, at least one oligosaccharide and at least one inhibitor of hyaluronic acid degradation. The invention is of use in particular in human dermatology or in reconstructive surgery.
    Type: Application
    Filed: April 22, 2008
    Publication date: October 27, 2011
    Inventors: Marc Moutet, Jean-Claude Yadan
  • Publication number: 20110256115
    Abstract: The invention relates to [6)O-?-D-Glcp-(1?]n-6-O-?-D-Glcp-(1?-phenolic derivatives. These [6)O-?-D-Glcp-(1?]n-6-O-?-D-Glcp-(1?-phenolic derivatives of selected phenolics are new, have a solubility in water higher than that of their parent O-?-D-Glcp-(1?-phenolic derivatives and have useful applications in cosmetic, nutrition and pharmaceutical compositions, such as treating or preventing oxidative stress, a cancer, a cardiovascular disease, a bacterial infection, a viral infection, a fungal infection, a UV-induced erythema, an allergy, a metabolism disorder, diabetes, an obesity, a hormonal disorder, a bone disease, a pain, a brain disease, a mouth or teeth disease, an inflammatory or immune disorder.
    Type: Application
    Filed: December 22, 2009
    Publication date: October 20, 2011
    Applicant: Libragen
    Inventors: Daniel Auriol, Aurélien Ginolhac, Fabrice Lefevre, Renaud Nalin
  • Patent number: 8039656
    Abstract: 4-(trifluoromethanesulfonyloxyphenyl)propionic acid derivatives and pharmaceutical composition containing such compounds are useful in inhibiting the chemotactic activation of neutrophils (PMN leukocytes) induced by the interaction of Interleukin-8 (IL-8) with CXCR1 and CXCR2 membrane receptors. The compounds are used for the prevention and treatment of pathologies deriving from said activation. Notably, these metabolites are devoid of cyclo-oxygenase inhibition activity and are particularly useful in the treatment of neutrophil-dependent pathologies such as psoriasis, ulcerative colitis, melanoma, chronic obstructive pulmonary disease (COPD), bullous pemphigoid, rheumatoid arthritis, idiopathic fibrosis, glomerulonephritis and in the prevention and treatment of damages caused by ischemia and reperfusion.
    Type: Grant
    Filed: March 21, 2005
    Date of Patent: October 18, 2011
    Inventors: Marcello Allegretti, Maria Candida Cesta, Riccardo Bertini, Marco Mosca, Francesco Colotta
  • Publication number: 20110243914
    Abstract: The invention relates to new compounds for cancer therapy or diagnosis and more specifically to the use of a non-toxic B subunit of Shiga toxin mutant as a vector for diagnostic products or drugs in over-expressing Gb3 receptor cells, such compounds having the following formula: STxB-Z(n)-Cys-Y(m)-T wherein STxB is the Shiga Toxin B subunit or a functional equivalent thereof, Z(n) whrein n is 0 or 1 and when n is 1, Z is an amino-acid residue devoidof sulfydryl group, or is a polypeptide, Cys is the amino-acid residue for Cysteine, T is a molecule linked by a covalent bound to the S part of Cys, selected in a group comprising: agents for in vivo diagnosis, cytotoxic agents, prodrugs, or enzymes for the conversion of a prodrug to a drug, Y(m) wherein m is 0 or 1 and when m is 1, Y is a linker between T and Cys, said linker being either cleavable or not cleavable for the release of T after the internalization of the hybrid compound into said cells.
    Type: Application
    Filed: June 13, 2011
    Publication date: October 6, 2011
    Inventors: Ludger JOHANNES, David Grierson, Sylvie Robine, Jean-Claude Florent, Philipe Maillard, Jacky Roger
  • Publication number: 20110229474
    Abstract: Compositions and methods for modulating human immunodeficiency virus (HIV) infection involving substances that inhibit the ability of high mobility box 1 (HMGB1) protein to interact with natural killer (NK) cells. Therapeutic compositions comprising antibodies and drugs, such as glycyrrhizin, which bind to HMGB1. Methods of detecting or monitoring HIV infection involving detection or quantitation of HMGB1 or antibodies specific for HMGB1 in a biological sample.
    Type: Application
    Filed: September 11, 2009
    Publication date: September 22, 2011
    Applicant: INSTITUT PASTEUR
    Inventors: Marie-Lise Gougeon, Hela Saidi, Maria-Therese Melki, Beatrice Poirier-Beaudoin, Valerie Seffer
  • Publication number: 20110230430
    Abstract: A saponin extract from Saponaria vaccaria and its use for stimulating apoptosis in cancer cells and treating cancer is described. The saponin extract may be isolated from Saponaria vaccaria seed. The saponin extract may comprise one or more than one triterpene saponin. The triterpene saponin may comprise a bisdesmosidic saponin having a molecular weight selected from the group consisting of molecular weight 1448, 1464, 1422, 1526, 1596 and 1688. Bisdesmosidic saponin of molecular weight 1448, 1464, 1422, 1526, 1596 and 1688 isolated from Saponaria vaccaria seed may be used to treat human cancer including prostate cancer, human breast cancer and colon cancer. Also disclosed is a method of isolating the saponin extract.
    Type: Application
    Filed: March 26, 2009
    Publication date: September 22, 2011
    Applicant: NATIONAL RESEARCH COUNCIL OF CANADA
    Inventors: Robert Hickie, John Balsevich, Irving Ramirez-Erosa, Donna Dunlop, Greg Bishop, Leah Deibert, Paul Arnison
  • Publication number: 20110224159
    Abstract: The instant application is directed to bidesmosidic betulin and betulinic acid saponin derivatives of formula (I), and use thereof as antitumor agents. In particular, said compounds are effective in treating lung carcinomas, colorectal adenocarcinomas, breast adenocarcinomas, and prostate adenocarcinomas. Methods of synthesizing said compounds through selective glycosylation of the C-28 and C-3 position, and diagnostic methods for identifying tumours suitable for treatment by said compounds are also disclosed.
    Type: Application
    Filed: September 10, 2009
    Publication date: September 15, 2011
    Applicant: Universite du Quebec a Chicoutime
    Inventors: André Pichette, Jean Legault, Charles Gauthier
  • Publication number: 20110224160
    Abstract: The present invention provides the use of escin for the manufacture of a pharmaceutical preparation for the treatment of a Type IV hypersensitivity reaction or symptoms of a Type IV hypersensitivity reaction, such as in contact dermatitis, atopic dermatitis, hypersensitivity pneumonitis, chronic transplant rejection, graft versus host disease, cell mediated autoimmune diseases, Hashimoto's thyroiditis, Sjogren's disease, adrenalitis, polymyositis, or pernicious anemia.
    Type: Application
    Filed: November 16, 2009
    Publication date: September 15, 2011
    Applicant: MARINOMED BIOTECHNOLOGIE GMBH
    Inventors: Eva Prieschl-Grassauer, Thomas Friedrich
  • Publication number: 20110218167
    Abstract: The invention describes novel triterpenoid 2-deoxy glycosides of general formula I, wherein at least one of the substituents X1 and R2 contains a 2-deoxy glycosidic group, method of preparation thereof, their cytotoxic activity and a pharmaceutical formulation containing these compounds.
    Type: Application
    Filed: November 6, 2009
    Publication date: September 8, 2011
    Inventors: Jan Sarek, Pavla Spácilová, Marian Hajduch
  • Publication number: 20110217252
    Abstract: It is described the use of propionyl L-carnitine for treating disturbances of the skin such as cellulite.
    Type: Application
    Filed: November 5, 2009
    Publication date: September 8, 2011
    Applicant: SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A.
    Inventor: Aleardo Koverech
  • Publication number: 20110201568
    Abstract: The present invention is successful in providing caffeic acid derivatives namely eicosanyl caffeate and docosyl caffeate from Glycyrrhiza. Also, the present invention provides a composition comprising said bio actives and also provides a process to prepare the composition. Ultimately, the invention provides solution for the management of ulcer.
    Type: Application
    Filed: November 25, 2009
    Publication date: August 18, 2011
    Inventor: Amit Agarwal
  • Patent number: 7998943
    Abstract: A method of treating a subject in need of therapy for a condition involving detrimental activity of the enzyme core 2 GlcNAc-T is provided, comprising administration of a therapeutically effective amount of an inhibitor of core 2 GlcNAc-T of the formula I to a patient in need thereof wherein R1 is H, —OH, C1-6 alkoxy, —NR5R6, or Sac 1; R2 is H, —OH, C1-6 alkoxy or Sac 2; R3 is H, —OH, C1-6 alkoxy or Sac 3; R4 is H, C1-6 alkyl, C1-6 hydroxyalkyl or C1-6-alkoxy-C1-6-alkyl; R5 is H, C1-6 alkyl or C1-6 acyl; R6 is H, C1-6 alkyl or C1-6 acyl; Sac 1 Sac 2 and Sac 3 are independently selected saccharide moieties, and Z is a steroid moiety; or a pharmaceutically acceptable salt, ether or ester form thereof.
    Type: Grant
    Filed: July 6, 2006
    Date of Patent: August 16, 2011
    Assignee: BTG International Limited
    Inventors: Rakesh Chibber, Russell Hagan
  • Patent number: 7998937
    Abstract: The present invention relates to a flavonoid compound having an antiviral activity, more particularly to a flavonoid compound obtained by extracting Houttuynia cordata with methanol and separating/purifying with chromatography, a method for efficient extraction and purification of the same and an antiviral composition comprising the compound as an active ingredient.
    Type: Grant
    Filed: November 3, 2006
    Date of Patent: August 16, 2011
    Assignee: Korea Research Institute of Bioscience and Biotechnology
    Inventors: Dur Han Kwon, Wha Jeong Choi, Choong Hwan Lee, Jin Hee Kim, Man Bae Kim
  • Patent number: 7985435
    Abstract: The invention provides saponin mixtures and compounds which are isolated from the species Acacia victoriae and methods for their use. These compounds may contain a triterpene moiety, such as acacic or oleanolic acid, to which oligosaccharides and monoterpenoid moieties are attached. The mixtures and compounds have properties related to the regulation of apoptosis and cytotoxicity of cells and exhibit potent anti-tumor effects against a variety of tumor cells.
    Type: Grant
    Filed: January 15, 2010
    Date of Patent: July 26, 2011
    Assignee: Research Development Foundation
    Inventors: Charles J. Arntzen, Mary E. Blake, Jordan U. Gutterman, Joseph J. Hoffmann, Gamini S. Jayatilake, David T. Bailey
  • Publication number: 20110171289
    Abstract: The present invention relates to a pharmaceutical combination for the treatment of diseases which involves cell proliferation, migration or apoptosis of myeloma cells, or angiogenesis. The invention also relates to a method for the treatment of said diseases, comprising co-administration of effective amounts of specific active compounds and/or co-treatment with radiation therapy, in a ratio which provides an additive and synergistic effect, and to the combined use of these specific compounds and/or radiotherapy for the manufacture of corresponding pharmaceutical combination preparations.
    Type: Application
    Filed: November 9, 2010
    Publication date: July 14, 2011
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Martin Friedrich STEFANIC, Frank HILBERG, Gerd MUNZERT, Flavio SOLCA, Anke BAUM, Jacobus C.A. van MEEL
  • Patent number: 7968596
    Abstract: The present invention relates to application of compounds of formula (1) (Gibberellins) and their derivatives for the preparation of a pharmaceutical composition or medicaments for the treatment of diabetes, its complications and associated conditions, including obesity, micro and macro vascular diseases, nephropathy, neuropathy, eye diseases, diabetic ulcerations and the like. The method results the normalization of serum glucose level and other physiological conditions.
    Type: Grant
    Filed: August 24, 2006
    Date of Patent: June 28, 2011
    Assignee: Australian Biomedical Company Pty, Ltd.
    Inventors: Peter James Jenkins, Minnie Wu, David Shine Wu
  • Publication number: 20110117008
    Abstract: The present invention provides compositions of avicins and avicin mixtures that enhance topical, percutaneous, transmucosal, transepithelial, transendothelial or transdermal transport of agents including diagnostic molecules, therapeutic drugs and cosmetic materials.
    Type: Application
    Filed: November 24, 2008
    Publication date: May 19, 2011
    Applicants: Research Development Foundation, Vanderbilt University
    Inventors: V. Prasad Shastri, Christopher Pino, Jordan Gutterman
  • Patent number: 7943184
    Abstract: The present invention relates to a process for preparing an extract from ivy leaves which includes the active ingredient hederacoside C and ?-hederin, and to extracts prepared by this process. According to this there is initially provision of a first, ?-hederin-rich extract and subsequently provision of a second, hederacoside C-rich extract. In a last step, the two extracts are blended to give an extract which has an adjusted hederacoside C content and an adjusted ?-hederin content.
    Type: Grant
    Filed: March 17, 2006
    Date of Patent: May 17, 2011
    Assignee: Engelhard Arzneimittel GmbH & Co. KG
    Inventors: Frank Runkel, Wolfgang Schneider, Oliver Schmidt, Georg Maximilian Engelhard
  • Publication number: 20110105406
    Abstract: The present invention relates to a cosmetic composition comprising: a) from about 0.05% to about 10% of a salt form active; b) from about 0.001% to about 2% of a thickening agent; and c) water, wherein the composition has a turbidity no higher than about 10 NTU, and has a pH in the range of about 5.0 to about 6.8.
    Type: Application
    Filed: October 29, 2010
    Publication date: May 5, 2011
    Applicant: The Proctor & Gamble Company
    Inventors: Chengwu Li, Xincheng Hu
  • Publication number: 20110104065
    Abstract: Described herein are progenitor cancer cells and cell lines isolated from human breast ductal carcinoma in situ (DCIS) lesions and the uses of these cells or cell lines in drug design, drug screening, and monitoring in vivo therapy. The DCIS malignant precursor cells or cell lines are epithelial in origin, are positive for markers of autophagy, show at least one genetic difference from normal cells of said fragment, form 3-D tube-like structures or ball aggregates, or are inhibited in formation of 3-D structures and migration by treatment with chloroquine. In one embodiment, there is a loss of heterozygosity (LOH) that is narrowly confined to a region of chromosome 6p (6p21.1-6p12.3) that contains the SUPT3H gene.
    Type: Application
    Filed: October 28, 2010
    Publication date: May 5, 2011
    Inventors: Virginia Espina, Lance Liotta
  • Patent number: 7923435
    Abstract: Extracts of Hoodia plant containing steroidal glycosides which have improved flavor, by virtue of reduced levels of discovered negative flavor compounds. Food compositions containing steroidal glycosides with reduced amounts of discovered negative flavor components are also included.
    Type: Grant
    Filed: April 21, 2008
    Date of Patent: April 12, 2011
    Assignee: Phytopharm PLC
    Inventors: Amir Maximiliaan Batenburg, Mohamed Said Chaara, Egge Aart Eddy Rosing, Frederik Michiel Meeuse, Salomon Leendert Abrahamse
  • Publication number: 20110071098
    Abstract: A topical pharmaceutical gel includes flurbiprofen or a pharmaceutically acceptable salt of flurbiprofen, thiocolchicoside or a pharmaceutically acceptable salt of thiocolchicoside, and menthol. Pharmaceutical combinations of flurbiprofen, thiocolchicoside, and menthol in the form of topical gels with anti-inflammatory, analgesic, and myorelaxant activities are described.
    Type: Application
    Filed: September 20, 2010
    Publication date: March 24, 2011
    Applicant: Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi
    Inventors: Fatih Cakir, Ali Turkyilmaz, Umit Cifter
  • Publication number: 20110065662
    Abstract: Aspects of the invention relate to compounds, extracts and compositions thereof, and methods of using of the same, to treat neurodegenerative disorders and/or improve brain health. In certain embodiments, said compounds are pomegranate flavonoids.
    Type: Application
    Filed: July 23, 2010
    Publication date: March 17, 2011
    Applicant: Amazentis SA
    Inventors: Christopher L. Rinsch, Philippe V. L. Dupraz
  • Publication number: 20110053877
    Abstract: A topical pharmaceutical formulation made up of nimesulide or a pharmaceutically acceptable derivative of nimesulide, together with thiocolchicoside or a pharmaceutically acceptable derivative of thiocolchicoside. The present invention more particularly relates to pharmaceutical combinations of nimesulide and thiocolchicoside, in the form of topical gels, ointments, cream, sprays, or lotions with anti-inflammatory, analgesic, and myorelaxant activities.
    Type: Application
    Filed: August 31, 2010
    Publication date: March 3, 2011
    Applicant: Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi
    Inventors: Fatih Cakir, Ali Turkyilmaz, Levent Oner, Umit Cifter
  • Publication number: 20110052727
    Abstract: The invention presents nutritional supplements with anti influenza activities. In a preferred embodiment, the invention features administration to a subject an effective dose of a nutritional supplement that includes a combination of all or some of the following ingredients licorice, quercetin, green tea, cinnamon, propolis, and selenium.
    Type: Application
    Filed: August 31, 2009
    Publication date: March 3, 2011
    Inventor: Hanan Polansky
  • Publication number: 20110027356
    Abstract: Oral pharmaceutical dosage form containing at least two medicaments, in which form the medicaments on the one hand are brought together in a leakproof and in-vivo water soluble wrapping and on the other hand are separated so that the active principle of the combined medicaments cannot come into contact with one another, at least one of the medicaments being selected from the following therapeutic classes: non-steroidal anti-inflammatory drug (NSAID), proton pump inhibitor (PPI), beta-blocker, statin, conversion enzyme inhibitor (CEI), biguanide, myorelaxant, calcium inhibitor, corticoid, antidepressant, benzodiazepine, non-atropine-like intestinal transit retarder, intestinal antibacterial, and the following therapeutic molecules: spironolactone, propranolol, clarithromycin, amoxycillin, low-dose acetylsalicylic acid, potassium, clopidogrel.
    Type: Application
    Filed: January 26, 2009
    Publication date: February 3, 2011
    Inventors: Anne-Emmanuelle Lugrin, Claude Griscelli, Mehdi El Glaoui, Guillaume El Glaoui, Jean Hoffelt
  • Publication number: 20110014204
    Abstract: The present invention relates to targets of loss of imprinting (LOI) affected IGF2 gene products in pre-malignant tissues, where methods of inhibiting those targets, including IGFR1, are disclosed to prevent tumor development in subjects at risk for developing colorectal cancer (CRC). The present invention also relates to methods of identifying increased risk in developing CRC in a subject, including methods of assessing the efficacy of a chemotherapeutic regimen. Further, the present invention relates to methods for identifying anti-neoplastic agents.
    Type: Application
    Filed: December 7, 2007
    Publication date: January 20, 2011
    Inventors: Andrew P. Feinberg, Andre Levchenko, Dan L. Longo, Minoru S.H. Ko
  • Publication number: 20110009352
    Abstract: There is provided a medicament capable of enhancing the antimicrobial peptide production ability. The medicament contains, as an active ingredient, a compound which is glycyrrhizin or a pharmaceutically acceptable salt thereof and capable of inhibiting the production of at least one of interleukin-10 (IL-10) and chemokine CCL2. The antimicrobial peptide is preferably defensin or cathelicidin.
    Type: Application
    Filed: July 7, 2010
    Publication date: January 13, 2011
    Applicant: Minophagen Pharmaceutical Co., LTD.
    Inventors: Fujio Suzuki, Makiko Kobayashi, Tokuichiro Utsunomiya, Tsuyoshi Yoshida, Shohei Yoshida
  • Publication number: 20110009351
    Abstract: The present invention relates to a novel assay or screen for identifying compounds with potential therapeutic value for the treatment of protein trafficking diseases such as Cystic Fibrosis (CF) and nephrogenic diabetes insipidus (NDI). The usual approach involves expressing the mutant form of the gene in cells and assaying function in a multiwell format when cells are exposed to libraries of compounds. Although such functional assays are useful, they do not directly test the ability of a compound to correct defective trafficking of the protein. To address this a novel corrector screening assay for CF has been developed in which the appearance of the mutant protein at the cell surface is measured as the assay output. This assay was used to screen more than 3100 compounds. This novel screening approach to protein trafficking diseases is robust and general, and may enable the selection of molecules that can be translated rapidly to a clinical setting.
    Type: Application
    Filed: May 9, 2008
    Publication date: January 13, 2011
    Inventors: David Y. Thomas, John Hanrahan, Graeme Carlile, Renaud Robert
  • Patent number: 7863321
    Abstract: The present invention relates to synergistic combinations of the compound 5, 6-dimethylxanthenone-4-acetic acid (DMXAA) and a compound selected from anthracyclines and topisomerase II inhibitors, which have anti-tumor activity. Preferably, the present invention relates to synergistic combinations of the compound 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and a compound selected from etoposide, and doxorubicin. More particularly, the invention is concerned with the use of such combinations in the treatment of cancer and pharmaceutical compositions containing such combinations. The invention further provides for methods of preparing the combinations of the invention.
    Type: Grant
    Filed: July 30, 2007
    Date of Patent: January 4, 2011
    Assignee: Cancer Research Technology Limited
    Inventors: William R. Wilson, Bronwyn G. Siim
  • Publication number: 20100331272
    Abstract: An agent for preventing or ameliorating skin aging, which exhibits a more excellent effect on the suppression of formation, or the amelioration, of wrinkles on the skin or sagging skin. An agent for preventing or ameliorating skin aging, containing triterpenoid saponins represented by the following formula (1) as an active ingredient, wherein at least one of R1 and R2 is a tigloyl group and the other represents a tigloyl group or an angeloyl group; R3 represents a methyl group or a hydroxymethyl group; and R4 represents Glc, Xyl or Gal.
    Type: Application
    Filed: February 26, 2009
    Publication date: December 30, 2010
    Applicant: KAO Corporation
    Inventors: Akiyo Kameyama, Tsutomu Fujimura
  • Publication number: 20100330176
    Abstract: The invention relates to the use of ambroxol and the pharmacologically acceptable salts thereof for preparing a pharmaceutical composition for the treatment of painful conditions in the oral and pharyngeal cavity.
    Type: Application
    Filed: August 23, 2010
    Publication date: December 30, 2010
    Applicant: BOEHRINGER INGELHEIM PHARMA GMBH AND CO. KG
    Inventors: Anke ESPERESTER, Uwe PSCHORN, Jean-Michel VIX
  • Patent number: 7854922
    Abstract: The present invention has an object to provide an external dermatological formulation having satisfactory blood flow-promoting effect, antiinflammatory effect, antibacterial effect, moisturizing effect, whitening effect, UV-absorbing effect, UV-scattering effect, antioxidant effect, hair growing effect, hair nourishing effect, emusifying effect, astringent effect, wrinkle-reducing effect, cell-activating effect and/or transdermal absorption-promoting effect with a satisfactory safety and skin feeling; The object is solved by providing an external dermatological formulation comprising a saccharide derivative of ?,?-trehalose and one or more members selected from substances having any one of blood flow-promoting effect, antiinflammatory effect, antibacterial effect, moisturizing effect, whitening effect, UV-absorbing effect, UV-scattering effect, antioxidant effect, hair growing efect, hair nourishing effect, emulsifying effect, astringent effect, wrinkle-reducing effect, cell-activating effect and transdermal
    Type: Grant
    Filed: February 10, 2004
    Date of Patent: December 21, 2010
    Assignee: Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo
    Inventors: Fujimi Tanabe, Michio Kubota, Hiromi Tatsukawa, Shigeharu Fukuda, Toshio Miyake
  • Publication number: 20100317606
    Abstract: This invention provides methods, processes, compounds and compositions for modulating the gene expression or secretion of adhesion proteins, angiopoietins or their receptors to cure diseases, for anti-angiogenesis and for treating parasites, wherein the adhesion proteins or receptors comprise fibronectin, integrins family, myosin, vitronectin, collagen, laminin, glycosylation cell surface proteins, polyglycans, cadherin, heparin, tenascin, CD 54, CAM, elastin and FAK; wherein the angiopoietins comprise angiopoietin 1, angiopoietin 2, angiopoietin 3, angiopoietin 4, angiopoietin 5, angiopoietin 6, angiopoietin 7, angiopoietin-like 1, angiopoietin-like 2, angiopoietin-like 3, angiopoietin-like 4, angiopoietin-like 5, angiopoietin-like 6, and angiopoietin-like 7; wherein the cancers comprise breast cancer, leukocyte cancer, liver cancer, ovarian cancer, bladder cancer, prostate cancer, skin cancer, bone cancer, brain cancer, leukemia cancer, lung cancer, colon cancer, CNS cancer, melanoma cancer, renal cancer, c
    Type: Application
    Filed: August 13, 2010
    Publication date: December 16, 2010
    Applicant: PACIFIC ARROW LIMITED
    Inventors: Pui-Kwong CHAN, May Sung MAK
  • Publication number: 20100310687
    Abstract: The present invention relates to a Momordicae semen extract effective in the prevention and treatment of gastritis or gastric ulcer and momordica saponin I isolated therefrom. The Momordicae semen extract and the momordica saponin I isolated therefrom is effective in the prevention and treatment of gastritis or gastric ulcer since they prevent the damage of the gastric mucosa caused by alcohols and inhibit the secretion of gastric acid.
    Type: Application
    Filed: August 16, 2010
    Publication date: December 9, 2010
    Applicant: SK Chemicals Co., Ltd.
    Inventors: Bong Cheol KIM, Joo Hyon Kim, Se Jun Yun, Eun Jung Noh, Gi Uk Jang, Chang-Kyun Han, Yong-Baik Cho, Wie-Jong Kwak
  • Publication number: 20100310684
    Abstract: Methods for treating and preventing mucositis, in particular mucositis following the administration of chemotherapy drugs or a combination of said drugs with radiotherapy, are disclosed herein. More specifically, disclosed herein is the administration of a therapeutically effective amount of at least one of an anthocyanoside, a proanthocyanidin, or an extract containing at least one of an anthocyanoside or a proanthocyanidin for the treatment or prevention of mucositis. The therapeutically effective amount of the anthocyanoside, proanthocyanidin or extract can be administered alone or in combination with a therapeutically effective amount of at least one of an anti-inflammatory agent, immunomodulating agent, analgesic, antimicrobial agent or antifungal agent. Also disclosed herein are pharmaceutical compositions for treating and preventing mucositis.
    Type: Application
    Filed: August 16, 2010
    Publication date: December 9, 2010
    Inventors: Ezio Bombardelli, Paolo Morazzoni
  • Publication number: 20100310487
    Abstract: An active ingredient combination which comprises a) glycerol monoalkyl ether, b) bispyridinium alkane, c) polyol and d) antioxidant. The combination is advantageously used for producing a preparation for the treatment of undesired body odour, for example for producing a cosmetic deodorant preparation, an antidandruff hair cleansing composition, a preparation for the treatment of blemished skin and acne or a preparation for the treatment of foot and/or skin fungus.
    Type: Application
    Filed: February 18, 2009
    Publication date: December 9, 2010
    Applicant: AIR LIQUIDE SANTE (INTERNATIONAL)
    Inventors: Wolfgang Beilfuss, Klaus Weber, Ralf Gradtke, Sabine Herwig
  • Publication number: 20100298250
    Abstract: Methods and compositions for treating at least one symptom of a viral infection, said method of treatment comprising administering to a subject with a least one symptom of a viral infection an effective dosage unit of a composition comprising pomegranate extract. The compositions comprise pomegranate extract comprising polyphenols. The composition is produced by a process comprising providing one or more pomegranate solids selected from the group consisting of a pericarp, inner membrane and seeds, creating a mixture comprising said one or more pomegranate solids in an aqueous solution, heating said mixture to a temperature that permits enzyme catalysis of said pomegranate solids, and removing residual insoluble solid materials from said mixture to provide said pomegranate extract. Compositions containing the extract may be used as a food product, beverage, pharmaceutical preparations, nutritional supplements, vitamin supplements, food additives, and food supplements.
    Type: Application
    Filed: March 23, 2010
    Publication date: November 25, 2010
    Inventors: Mohammad MADJID, Harley R. Liker
  • Publication number: 20100298251
    Abstract: The present invention relates to Momordicae semen extract having wound-healing efficiencies. In particular, the present invention relates to a wound-healing topical transdermal agent comprising an active ingredient of Momordicae semen extract, which is capable of reducing the time required for the closure and treatment of wounds as confirmed in skin-wound induced animal model.
    Type: Application
    Filed: October 21, 2008
    Publication date: November 25, 2010
    Inventors: Bongcheol Kim, Joo-Hyun Kim, Se-Jun Yun, Gi-Uk Jang, Sungsoo Pyo
  • Publication number: 20100298249
    Abstract: The invention relates to a pharmaceutical or cosmetic composition for topical and/or parenteral application comprising, in a physiologically acceptable medium, at least one retinoid or salts and derivatives thereof, and at least one inhibitor of hyaluronic acid degradation. The invention is of use in particular in human dermatology or in reconstructive surgery.
    Type: Application
    Filed: April 22, 2008
    Publication date: November 25, 2010
    Inventors: Marc Moutet, Jean-Claude Yadan